Compare AHMA & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AHMA | SWKH |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Diversified Financial Services |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 175.5M |
| IPO Year | 2025 | 1999 |
| Metric | AHMA | SWKH |
|---|---|---|
| Price | $7.09 | $16.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 2.8M | 10.2K |
| Earning Date | 12-08-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 120.89 |
| EPS | 0.03 | ★ 1.85 |
| Revenue | $18,543,447.00 | ★ $40,149,000.00 |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $213.20 | ★ $9.12 |
| Revenue Growth | N/A | ★ 62.38 |
| 52 Week Low | $4.00 | $13.17 |
| 52 Week High | $18.20 | $20.49 |
| Indicator | AHMA | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 56.01 |
| Support Level | N/A | $16.72 |
| Resistance Level | N/A | $17.75 |
| Average True Range (ATR) | 0.00 | 0.32 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 46.15 |
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.